期刊
CURRENT OPINION IN PHARMACOLOGY
卷 68, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2022.102345
关键词
-
Polycystic ovary syndrome is a common endocrine disorder characterized by excessive levels of androgen and anovulatory infertility. It is also associated with comorbidities such as obesity, hyperinsulinemia, and increased risk of cardiovascular complications. The symptoms related to reproduction, endocrine, and metabolism vary greatly, posing challenges for clinical management.
Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of car-diovascular complications. Reproductive, endocrine, and metabolic symptoms are highly variable, with heterogenous phenotypes adding complexity to clinical management of symptoms. This review highlights recent findings regarding emerging therapies for treating polycystic ovary syndrome, including i) pharmacological agents to target androgen excess, ii) modulation of kisspeptin signalling to target central neuro-endocrine dysregulation, and iii) novel insulin sensitisers to combat peripheral metabolic dysfunction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据